Juvenile Idiopathic Arthritis NewsLatest News On Juvenile Idiopathic Arthritis FDA Approves Third Tocilizumab Biosimilar2/3/2025 1:45 AM Quality Improvement Initiative Reduced Juvenile Idiopathic Arthritis Racial Disparities at Single Institution12/5/2024 12:50 AM Burden of Noninfectious Uveitis on Quality of Life11/14/2024 6:28 AM Use of New DMARDs for Juvenile Idiopathic Arthritis Rose Steadily in Past 20 Years11/1/2024 6:14 AM Emapalumab Effective in Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis9/26/2024 1:46 AM Support Program Boosts Health in Juvenile Arthritis Patients8/28/2024 1:18 AM Canakinumab Effective as First-Line Drug for Systemic Juvenile Idiopathic Arthritis Without Steroids6/26/2024 4:14 AM Phase 3 Trial Supports Ixekizumab in Treatment of Juvenile PsA, Enthesitis-Related Arthritis6/20/2024 2:54 AM FDA OKs Sarilumab for Polyarticular Juvenile Idiopathic Arthritis6/11/2024 1:53 PM Medicare Part D Plans Poorly Cover Adalimumab Biosimilars6/6/2024 9:53 AM FDA Extends Upadacitinib Indications to Children With Arthritis6/4/2024 3:51 PM Friendswood star softball player overcomes rare, juvenile arthritis condition6/2/2024 10:03 PM FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo5/2/2024 11:04 AM Two Biosimilars Approved in Europe for Autoimmune Disorders4/26/2024 10:17 AM Subcutaneous Tocilizumab Gives Durable Long-Term Response in Juvenile Idiopathic Arthritis Subtypes4/12/2024 3:56 AM Tocilizumab Withdrawal Post Remission in Still's Disease4/11/2024 1:53 AM
